French engineering firm specializing in sensor systems, medical imaging instrumentation, and detection technologies for European research consortia.
Lyon Ingénierie Projets (LIP) is a French engineering services firm based in Villeurbanne (Lyon metropolitan area) that provides technical engineering, project management, and systems integration support to European research and innovation consortia. Their recurring involvement in projects spanning medical imaging, radiation detection, biosensors, and nanomaterials points to core competencies in instrumentation engineering, sensor system design, and prototype development. They serve as a technical execution partner — translating scientific concepts into engineered prototypes and integrated systems across health, detection, and materials domains.
Central to SPCCT (spectral photon counting CT for cardiovascular/neurovascular imaging), SCANnTREAT (spectral scanner CT for cancer photodynamic therapy), and QUALITOP (quality of life monitoring post-immunotherapy).
SPARTE project focused on scintillating porous architectures for radioactive gas detection, combining optical materials engineering with metrology.
BIONANOSENS project on biomolecular electronics using smart nanomaterials for transducer and biosensor development.
FAPIC project on fast assay development for pathogen identification and characterisation.
HEARTEN (mHealth for heart failure management) and QUALITOP (digital monitoring platform for cancer immunotherapy patients).
SCANnTREAT combines hybrid nanoparticles with X-ray activation for photodynamic cancer therapy — an emerging therapeutic engineering domain for LIP.
LIP's early H2020 participation (2015–2018) centered on health-oriented engineering: mobile health platforms (HEARTEN), rapid diagnostic devices (FAPIC), and medical imaging hardware (SPCCT). From 2020 onward, their portfolio expanded significantly into advanced detection and materials — radiation metrology with scintillators (SPARTE), nanomaterial-based biosensors (BIONANOSENS), and nanoparticle-triggered cancer treatment (SCANnTREAT). This shift suggests the company moved from primarily supporting clinical health device projects toward deeper involvement in sensor engineering, advanced materials integration, and physics-based detection systems.
LIP is moving toward advanced sensor systems and nanomaterial-based detection technologies, making them an increasingly relevant partner for projects requiring instrumentation engineering at the intersection of physics and biomedical applications.
LIP operates exclusively as a consortium participant — across all 8 projects they have never coordinated, indicating they position themselves as a reliable technical contributor rather than a project leader. With 65 unique partners across 17 countries, they demonstrate a broad and non-exclusive network, joining diverse consortia rather than repeatedly partnering with the same groups. This pattern suggests they are valued for portable engineering skills that different research teams can plug into their projects as needed.
LIP has collaborated with 65 distinct partners across 17 countries, reflecting a wide European network built through diverse health, detection, and materials projects. Their base in Lyon — a major French biomedical and engineering hub — likely facilitates connections with both academic and industrial partners across the continent.
LIP occupies a distinctive niche as a private engineering firm that bridges physics-based detection systems and biomedical applications — a combination rarely found in a single non-academic partner. Their ability to contribute meaningfully to projects ranging from spectral CT imaging to radioactive gas sensors to biosensor electronics demonstrates unusual technical breadth in instrumentation. For consortium builders, LIP offers an industrially-minded engineering partner that can handle prototype development and systems integration without the overhead or IP constraints of a large corporation.
